NASCITA Italian birth cohort study: a study protocol.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
19 02 2020
Historique:
received: 19 04 2019
accepted: 06 02 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 13 3 2021
Statut: epublish

Résumé

Young children's healthy development depends on nurturing care, which ensures health, nutrition, responsive caregiving, safety and security, and early learning. Infancy and childhood are characterized by rapid growth and development, and these two factors contribute largely to determining health status and well-being across the lifespan. Identification of modifiable risk factors and prognostic factors during the critical periods of life will contribute to the development of effective prevention and intervention strategies. The NASCITA (NAscere e creSCere in ITAlia) study was created to evaluate physical, cognitive, and psychological development, health status and health resource utilization during the first six years of life in a cohort of newborns, and to evaluate potential associated factors. NASCITA is an ongoing, dynamic, prospective, population-based birth cohort study of an expected number of more than 5000 newborns who will be recruited in 22 national geographic clusters starting in 2019. It was designed to follow children from birth to school entry age for a wide range of determinants, disorders, and diseases. Recruitment of the newborns (and their parents) will take place during the first routine well-child visit, which takes place at the office of the pediatrician assigned to them by the local health unit of residence, and which is scheduled for all newborns born in Italy within the first 45 days of their life. Data will be web-based and collected by the family pediatricians during each of the 7 standard well-child visits scheduled for all children during their first 6 years of life. Information on every contact with the enrolled children in addition to these prescheduled visits will be also recorded. The NASCITA cohort study provides a framework in which children are followed from birth to six-years of age. NASCITA will broaden our understanding of the contribution of early-life factors to infant and child health and development. NASCITA provides opportunities to initiate new studies, also experimental ones, in parts of the cohort, and will contribute relevant information on determinants and health outcomes to policy and decision makers. Cohort details can be found on https://coortenascita.marionegri.it. Clinicaltrials.gov: NCT03894566. Ethics committee approval: 6 February 2019, Verbale N 59.

Sections du résumé

BACKGROUND
Young children's healthy development depends on nurturing care, which ensures health, nutrition, responsive caregiving, safety and security, and early learning. Infancy and childhood are characterized by rapid growth and development, and these two factors contribute largely to determining health status and well-being across the lifespan. Identification of modifiable risk factors and prognostic factors during the critical periods of life will contribute to the development of effective prevention and intervention strategies. The NASCITA (NAscere e creSCere in ITAlia) study was created to evaluate physical, cognitive, and psychological development, health status and health resource utilization during the first six years of life in a cohort of newborns, and to evaluate potential associated factors.
METHODS
NASCITA is an ongoing, dynamic, prospective, population-based birth cohort study of an expected number of more than 5000 newborns who will be recruited in 22 national geographic clusters starting in 2019. It was designed to follow children from birth to school entry age for a wide range of determinants, disorders, and diseases. Recruitment of the newborns (and their parents) will take place during the first routine well-child visit, which takes place at the office of the pediatrician assigned to them by the local health unit of residence, and which is scheduled for all newborns born in Italy within the first 45 days of their life. Data will be web-based and collected by the family pediatricians during each of the 7 standard well-child visits scheduled for all children during their first 6 years of life. Information on every contact with the enrolled children in addition to these prescheduled visits will be also recorded.
DISCUSSION
The NASCITA cohort study provides a framework in which children are followed from birth to six-years of age. NASCITA will broaden our understanding of the contribution of early-life factors to infant and child health and development. NASCITA provides opportunities to initiate new studies, also experimental ones, in parts of the cohort, and will contribute relevant information on determinants and health outcomes to policy and decision makers. Cohort details can be found on https://coortenascita.marionegri.it.
TRIAL REGISTRATION
Clinicaltrials.gov: NCT03894566. Ethics committee approval: 6 February 2019, Verbale N 59.

Identifiants

pubmed: 32075601
doi: 10.1186/s12887-020-1961-1
pii: 10.1186/s12887-020-1961-1
pmc: PMC7029570
doi:

Banques de données

ClinicalTrials.gov
['NCT03894566']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Références

Lancet. 2017 Jan 7;389(10064):77-90
pubmed: 27717614
Acta Paediatr. 2014 Dec;103(12):e532-7
pubmed: 25164591
Health Place. 2015 May;33:25-36
pubmed: 25744220
Thorax. 2018 Nov;73(11):1049-1061
pubmed: 29748253
ScientificWorldJournal. 2012;2012:154910
pubmed: 22536121
Pediatrics. 2014 Mar;133(3):e505-12
pubmed: 24534400
Lancet Glob Health. 2015 Aug;3(8):e458-e469
pubmed: 26144389
J Atten Disord. 2018 Oct;22(12):1173-1184
pubmed: 26320120
Respir Med. 2009 Jan;103(1):104-8
pubmed: 18760577
Eur J Clin Pharmacol. 2001 Oct;57(8):611-6
pubmed: 11758641
BMC Pediatr. 2014 Feb 07;14:36
pubmed: 24506846
Epidemiol Prev. 2018 Mar-Apr;42(2):121-126
pubmed: 29774708
Pediatr Res. 2014 Nov;76(5):418-24
pubmed: 25122581
Paediatr Perinat Epidemiol. 2013 Jul;27(4):393-414
pubmed: 23772942
Health Policy. 2018 Apr;122(4):334-351
pubmed: 29373188
PLoS Med. 2005 Sep;2(9):e250
pubmed: 16104833
Early Hum Dev. 2010 Dec;86(12):765-72
pubmed: 20846796
Environ Health. 2012 Jun 27;11:42
pubmed: 22715989
Int J Epidemiol. 2009 Aug;38(4):897-902
pubmed: 19561329
Obesity (Silver Spring). 2006 May;14(5):765-9
pubmed: 16855183
Arch Dis Child. 2012 Jan;97(1):73-7
pubmed: 21460403
Int J Immunopathol Pharmacol. 2016 Jun;29(2):308-19
pubmed: 26936651
BMC Health Serv Res. 2015 Sep 10;15:371
pubmed: 26357948
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Ann Epidemiol. 2017 Sep;27(9):583-592.e5
pubmed: 28911983
J Pediatr. 2016 Oct;177S:S116-S126
pubmed: 27666260

Auteurs

Claudia Pansieri (C)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Antonio Clavenna (A)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Chiara Pandolfini (C)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. chiara.pandolfini@marionegri.it.

Michele Zanetti (M)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Maria Grazia Calati (MG)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Daniela Miglio (D)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Massimo Cartabia (M)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Federica Zanetto (F)

President Associazione Culturale Pediatri (ACP), Narbolia, Italy.

Maurizio Bonati (M)

Laboratory for Mother and Child Health, Department of Public Health, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH